InvestorsHub Logo
Followers 468
Posts 26926
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 92

Thursday, 08/04/2011 8:49:58 AM

Thursday, August 04, 2011 8:49:58 AM

Post# of 145
7:16AM On The Wires (WIRES) :

Dyax Corp. (DYAX) announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme inhibitor-induced angioedema.


surf's up......crikey